Home Clinical Topics FDA approves Perjeta for late-stage breast cancer

FDA approves Perjeta for late-stage breast cancer

Author(s):

On June 8, the U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage breast cancer. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here